Park Ha Biological Technology is trading at $3.10, up 7.84%, with no clear company-specific catalyst identified for the September 25 move.
- The advance extends from $2.87 on September 24, 2026.
- Renewed coverage of a securities-class-action lawsuit alleging misleading disclosures and a pump-and-dump scheme is a negative risk factor, not an explicit explanation for the gain.
- Broader indexes are modestly higher, but not enough to provide a strong market-wide explanation.